LSE:GSKPharmaceuticals
GSK (LSE:GSK) Signed A $750 Million Oncology Deal
GSK (LSE:GSK) agreed a $750 million deal with Chimagen Biosciences for global rights to a dual-targeted multiple myeloma immunotherapy.
The pharmaceutical group reported registrational data to support Jideytro as a first-line treatment for ROS1-positive NSCLC.
GSK also released positive phase III trial results for Ris-Rez in relapsed small cell lung cancer.
The fresh Jideytro and Ris-Rez data, plus the Chimagen deal, sit within a wider oncology picture our research has mapped. We have also...